Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status

Clinical Pharmacology and Therapeutics
D R SohnT Ishizaki

Abstract

To assess the possible involvement of CYP2C19 in the metabolism of lansoprazole in vivo. Sixteen male Korean subjects, who had been phenotyped as extensive metabolizers and poor metabolizers of S-mephenytoin 4'-hydroxylation polymorphism (n = 8 each) with racemic mephenytoin with use of the 8-hour urine analysis of 4'-hydroxymephenytoin, took an oral dose of 30 mg lansoprazole, and blood samples were collected up to 48 hours after dosing. Lansoprazole and its metabolites were measured by high-performance liquid chromatography with ultraviolet detection. The mean lansoprazole area under the concentration-time curve (AUC), elimination half-life (t1/2), and apparent oral clearance (CLoral) were significantly (p < 0.001) greater, longer, and lower, respectively, in the poor metabolizer than in the extensive metabolizer group. The mean values for the AUC of hydroxylansoprazole and AUC ratio of hydroxylansoprazole to lansoprazole were significantly (p < 0.01 to p < 0.001) less in the poor metabolizer than in the extensive metabolizer group, whereas those for the AUC of lansoprazole sulfone and ratio of lansoprazole sulfone to lansoprazole were greater (p < 0.001) in the former than in the latter group. In addition, the log10 4'-hydro...Continue Reading

References

Jan 1, 1990·European Journal of Clinical Pharmacology·G AlvánU Gundert-Remy
Jan 1, 1989·Pharmacology & Therapeutics·G R WilkinsonR A Branch
Jan 1, 1989·Clinical Pharmacology and Therapeutics·S A WardR A Branch
Apr 1, 1985·British Journal of Clinical Pharmacology·M JurimaW Kalow
Jan 1, 1984·European Journal of Clinical Pharmacology·A Küpfer, R Preisig
Dec 1, 1984·Clinical Pharmacology and Therapeutics·P J WedlundR A Branch
Jun 9, 1995·Journal of Chromatography. B, Biomedical Applications·M D KarolK Alexander
Jun 1, 1995·Clinical Pharmacokinetics·B D LandesB Flouvat
Sep 1, 1994·Clinical Pharmacokinetics·J Brockmöller, I Roots
Feb 22, 1994·Biochemistry·J A GoldsteinB I Ghanayem
Jan 1, 1994·Alimentary Pharmacology & Therapeutics·G T Tucker
Jan 1, 1993·European Journal of Clinical Pharmacology·B Delhotal-LandesM Lemaire
Dec 1, 1993·British Journal of Clinical Pharmacology·T AnderssonD J Birkett
Nov 1, 1993·British Journal of Clinical Pharmacology·Z HusseinJ I Isenberg

❮ Previous
Next ❯

Citations

Oct 27, 2001·British Journal of Clinical Pharmacology·J A Goldstein
May 17, 2014·World Journal of Gastroenterology : WJG·Jyh-Chin YangChun-Jung Lin
Mar 9, 2005·British Journal of Clinical Pharmacology·Masato SaitoTomonori Tateishi
Apr 12, 2003·Pharmacotherapy·Elaine Chong, Mary H H Ensom
Jun 21, 2005·British Journal of Clinical Pharmacology·Masatomo MiuraToshio Suzuki
Dec 9, 2009·Expert Opinion on Drug Metabolism & Toxicology·Jyh-Chin Yang, Chun-Jung Lin
May 10, 2011·Expert Opinion on Drug Metabolism & Toxicology·Saskia N de Wildt
Apr 28, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Dan ZhangHuichen Liu
May 23, 2012·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Dan ZhangHuichen Liu
Jul 29, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Kenji IkemuraMasahiro Okuda
Oct 22, 2004·Journal of Clinical Pharmacology·Norio Yasui-FurukoriTomonori Tateishi
Jan 12, 2007·Clinical Pharmacology and Therapeutics·T FurutaA Hishida
Sep 30, 2000·Alimentary Pharmacology & Therapeutics·K AdachiY Kinoshita
Sep 24, 1999·Alimentary Pharmacology & Therapeutics·T Ishizaki, Y Horai
Nov 1, 2001·Alimentary Pharmacology & Therapeutics·Y HoraiT Ishizaki
Apr 15, 2008·Clinical Drug Investigation·Tommy Andersson, Lars Weidolf
Mar 12, 2003·The Pharmacogenomics Journal·D A Flockhart, J M Rae
Sep 12, 2002·Clinical Pharmacokinetics·Zeruesenay DestaDavid A Flockhart
Nov 9, 2000·Clinical Pharmacokinetics·D A FlockhartS K Mahal
Aug 30, 2012·Expert Review of Gastroenterology & Hepatology·Silvia Marelli, Fabio Pace
Sep 14, 2006·Pharmacological Reviews·Sharon J Gardiner, Evan J Begg
Mar 19, 2016·Alimentary Pharmacology & Therapeutics·T KagamiT Furuta
Jan 7, 1999·The Journal of Pharmacy and Pharmacology·K ArimoriM Nakano
Jan 7, 2003·Paediatric Drugs·Troy E Gibbons, Benjamin D Gold
Mar 27, 2003·Alimentary Pharmacology & Therapeutics·M KawamuraUNKNOWN Study Group of GERD
Sep 17, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Kyoung-Ah KimJae-Gook Shin
Feb 19, 2020·Current Drug Metabolism·Bhuvanachandra PasupuletiOm Prakash Prasad
Jan 12, 2002·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·M DojoM Kuriyama

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.